Preoperative Treatment of HR+/HER2+Breast Cancer With Pirotinib, Trastuzumab and AI Research

Inclusion Criteria

• •Female initial treatment patients aged ≥ 18 years and ≤ 75 years old
• •ECOG score 0-1
• •Stage II-IIIA invasive breast cancer, diameter ≥ 20mm
• •HER2 positive (IHC score of 3+, or 2+and ISH test positive)
• •ER\>10%
• •Doctors choose to use letrozole/anastrozole for endocrine therapy
• •The definition of menopause includes any of the following: (Previous bilateral oophorectomy; Age)≥ 60 years old; Age\<60 years old and without chemotherapy, tamoxifen, toremifen, or ovarian suppressionUnder normal conditions, menopause lasts for ≥ 12 months, and follicle stimulating hormone (FSH) and estradiol are within the postmenopausal range;If receiving tamoxifen or toremifen and age\<60 years, FSH and plasma estradiolWithin the postmenopausal range)
• •Left ventricular ejection fraction (LVEF) ≥ 50%
• •12 lead electrocardiogram: QT interval (QTcF) corrected by Fridericia method for females\<470ms；
• •The functional level of the main organs must meet the following requirements: blood routine: ANC ≥ 1.5 × 109/L； PLT≥90 × 109/L； Hb≥90 g/L；Blood biochemistry: TBIL ≤ 2.5 × ULN； ALT and AST ≤ 2.5 × ULN； BUN and Cr ≤ 1.5 × ULN；
• •For female subjects who have not undergone menopause or surgical sterilization, during the treatment period and during the study treatment
• •Agree to abstain or use effective contraceptive methods for at least 2 months after the next administration; .Volunteer to join this study, sign informed consent, have good compliance, and be willing to cooperate with follow-up.